Highmark, AstraZeneca Enter Outcomes-Based Agreement for Severe Asthma...

Highmark announced that it has entered an outcomes-based agreement with AstraZeneca for Fasenra, an add-on prescription maintenance treatment for patients age 12 or older with severe asthma. Through...(PRWeb September 21, 2020)Read the full story at https://www.prweb.com/releases/highmark_astrazeneca_enter_outcomes_based_agreement_for_severe_asthma_medication_fasenra/prweb17392252.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news